Sanofi and IGM ink $6 billion antibody collaboration deal

Deal will see pair use IGM's proprietary immunoglobulin M antibody platform to develop six agonists.

On Tuesday, the pharmaceutical giant announced it had entered an agreement with IGM Biosciences that could be worth up to $6 billion. The agreement is centred around IGM's engineered IgM antibody agonists, which are said to offer 'superior features' over traditional IgC antibodies when it comes to stimulating cell surface receptors. “We look forward to this collaboration with IGM Biosciences, a pioneer in a new class of antibody medicines for the treatment of cancer, immunology, and inflammatory diseases. The IGM Biosciences technology platform offers an exciting approach to developing high-avidity IgM antibodies that can efficiently bind and stimulate the activity of cell surface receptors. This unique platform has the potential to overcome historical limitations of conventional IgG antibodies when seeking agonists of some classes of receptors.” said John Reed, Global Head of Research and Development, Sanofi.

Per the terms of the agreement, the biotech could also receive up to $6 billion aligned with development, regulatory and commercial milestones. “Sanofi is a global leader in the development and commercialization of innovative therapies, and we welcome the addition of their extensive expertise and resources in expanding and accelerating the development of our IgM antibody platform across multiple areas of high unmet need. This partnership builds on an existing research collaboration with Sanofi and is a key step towards our goal of unlocking the full breadth of potential for this important new class of therapeutics. We are pleased to share this vision with Sanofi and look forward to working together on these six potentially first- and best-in-class programs.” added Fred Schwarzer, CEO of IGM.